<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40852006</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>14</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2049-0801</ISSN><JournalIssue CitedMedium="Print"><Volume>87</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Annals of medicine and surgery (2012)</Title><ISOAbbreviation>Ann Med Surg (Lond)</ISOAbbreviation></Journal><ArticleTitle>Once-weekly insulin icodec vs. daily insulin glargine in type 2 diabetes: a meta-analysis with longitudinal insights.</ArticleTitle><Pagination><StartPage>4452</StartPage><EndPage>4466</EndPage><MedlinePgn>4452-4466</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/MS9.0000000000003392</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Type 2 diabetes mellitus (T2DM) is a progressive condition often necessitating insulin therapy for sustained glycemic control, yet adherence to daily injections remains a significant challenge. While insulin glargine is effective, reducing injection frequency may improve compliance and outcomes. This study evaluates the efficacy and safety of once-weekly insulin icodec compared to once-daily insulin glargine U100.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">This systematic review and meta-analysis followed Cochrane and PRISMA guidelines. A comprehensive search across multiple databases identified randomized controlled trials (RCTs) comparing once-weekly insulin icodec with once-daily insulin glargine U100 in adults with T2DM. Eligible studies included adult participants and reported glycemic or safety outcomes. Data synthesis was performed using a random-effects model, with heterogeneity assessed via the I<sup>2</sup> statistic.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Five RCTs comprising 2,019 participants met the inclusion criteria. Insulin icodec significantly reduced glycated hemoglobin (MD:&#xa0;-0.12; 95% CI:&#xa0;-0.20,&#xa0;-0.04; <i>P</i> =&#xa0;0.003) and increased time in range (TIR; MD: 4.23; 95% CI: 2.20, 6.26; <i>P</i> &lt; 0.0001) compared to insulin glargine. A modest increase in body weight was observed with insulin icodec, while safety profiles, including hypoglycemia rates and adverse events, were comparable between treatments.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Insulin icodec provides a safe and effective alternative to once-daily insulin glargine for T2DM management, offering similar glycemic control with a once-weekly dosing regimen. The reduced injection burden may enhance adherence and treatment satisfaction, potentially improving long-term disease outcomes.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Author(s). Published by Wolters Kluwer Health, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ashraf</LastName><ForeName>Taimoor</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medicine, Nishtar Medical University, Multan, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Akshy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tara</LastName><ForeName>Aniket</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Memon</LastName><ForeName>Naila</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Medicine, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muhammad</LastName><ForeName>Areej</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turesh</LastName><ForeName>Muskan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, Ghulam Muhammad Mahar Medical College, Sukkur, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dev</LastName><ForeName>Shah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, Ghulam Muhammad Mahar Medical College, Sukkur, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muhammad</LastName><ForeName>Noor</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Vikash</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hussain</LastName><ForeName>Tooba</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medicine, Dow Medical College, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Ravesh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medicine, Dow Medical College, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Ajeet</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Dow Medical College, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bajaj</LastName><ForeName>Simran</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, Shaheed Mohtarma Benazir Bhutto Medical University, Larkana.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qammar</LastName><ForeName>Asfia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Dow Medical College, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deepak</LastName><ForeName>Fnu</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Medicine, Shaheed Mohtarma Benazir Bhutto Medical College Lyari, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kumar</LastName><ForeName>Aadesh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Jinnah Sindh Medical University, Karachi, Pakistan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yusuf</LastName><ForeName>Salih Abdella</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Medicine, Hawassa University, Hawassa, Ethiopia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Med Surg (Lond)</MedlineTA><NlmUniqueID>101616869</NlmUniqueID><ISSNLinking>2049-0801</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">glycemic control</Keyword><Keyword MajorTopicYN="N">once-daily insulin glargine</Keyword><Keyword MajorTopicYN="N">once-weekly insulin icodec</Keyword><Keyword MajorTopicYN="N">safety profile</Keyword><Keyword MajorTopicYN="N">type 2 diabetes mellitus</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>12</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>26</Day><Hour>8</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>26</Day><Hour>8</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>25</Day><Hour>5</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>6</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40852006</ArticleId><ArticleId IdType="pmc">PMC12369795</ArticleId><ArticleId IdType="doi">10.1097/MS9.0000000000003392</ArticleId><ArticleId IdType="pii">AMSU-D-25-00011</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>You SF, Zheng JY, Chen YP, et al. Research progress on the mechanism of beta-cell apoptosis in type 2 diabetes mellitus. Front Endocrinol (Lausanne) 2022;13:976465.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9434279</ArticleId><ArticleId IdType="pubmed">36060972</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinke C, Buchmann N, Fink A, et al. Diabetes duration and the risk of dementia: a cohort study based on German health claims data. Age Ageing 2022;51:afab231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8753043</ArticleId><ArticleId IdType="pubmed">34923587</ArticleId></ArticleIdList></Reference><Reference><Citation>Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adherence 2016;10:1299&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4966497</ArticleId><ArticleId IdType="pubmed">27524885</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SH, Yoon KH. A century of progress in diabetes care with insulin: a history of innovations and foundation for the future. Diabetes Metab J 2021;45:629&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8497924</ArticleId><ArticleId IdType="pubmed">34610718</ArticleId></ArticleIdList></Reference><Reference><Citation>Escalada J, Orozco-Beltran D, Morillas C, et al. Attitudes towards insulin initiation in type 2 diabetes patients among healthcare providers: a survey research. Diabetes Res Clin Pract 2016;122:46&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">27810685</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarbacker GB, Urteaga EM. Adherence to insulin therapy. Diabetes Spectr 2016;29:166&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5001221</ArticleId><ArticleId IdType="pubmed">27574371</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Nieves M, Boye KS, Kiljanski J, et al. Adherence to basal insulin therapy among people with type 2 diabetes: a retrospective cohort study of costs and patient outcomes. Diabetes Ther 2018;9:1099&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5984924</ArticleId><ArticleId IdType="pubmed">29644618</ArticleId></ArticleIdList></Reference><Reference><Citation>Okemah J, Peng J, Qui&#xf1;ones M. Addressing clinical inertia in type 2 diabetes mellitus: a review. Adv Ther 2018;35:1735&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6223992</ArticleId><ArticleId IdType="pubmed">30374807</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau ANC, Tang T, Halapy H, et al. Initiating insulin in patients with type 2 diabetes. CMAJ. 2012;184:767&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3328521</ArticleId><ArticleId IdType="pubmed">22470171</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilgenfeld R, Seipke G, Berchtold H, et al. The evolution of insulin glargine and its continuing contribution to diabetes care. Drugs 2014;74:911&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4045187</ArticleId><ArticleId IdType="pubmed">24866023</ArticleId></ArticleIdList></Reference><Reference><Citation>Polonsky WH, Fisher L, Hessler D, et al. Patient perspectives on once-weekly medications for diabetes. Diabetes Obes Metab 2011;13:144&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">21199266</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura E, Pridal L, Glendorf T, et al. Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing. BMJ Open Diabetes Res Care 2021;9:e002301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8378355</ArticleId><ArticleId IdType="pubmed">34413118</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xf6;velmann U, Br&#xf8;ndsted L, Kristensen NR, et al. 237-OR: insulin icodec: an insulin analog suited for once-weekly dosing in type 2 diabetes. Diabetes 2020;69:237-OR</Citation></Reference><Reference><Citation>Heise T, Chien J, Beals J, et al. Basal insulin fc (BIF), a novel insulin suited for once weekly dosing for the treatment of patients with diabetes mellitus. J Endocr Soc 2021;5:A329&#x2013;A329.</Citation></Reference><Reference><Citation>Ahmed M, Shafiq A, Javaid H, et al. Clinical outcomes with once-weekly insulin icodec versus once-daily insulin glargine u100 in insulin-na&#xef;ve and previously insulin-treated individuals with type 2 diabetes: a meta-analysis of randomised controlled trials. Endocrinol Diabetes Metab 2024;7:e00480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11043492</ArticleId><ArticleId IdType="pubmed">38659132</ArticleId></ArticleIdList></Reference><Reference><Citation>Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev 2019;10:ED000142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10284251</ArticleId><ArticleId IdType="pubmed">31643080</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg 2021;88:105906.</Citation><ArticleIdList><ArticleId IdType="pubmed">33789826</ArticleId></ArticleIdList></Reference><Reference><Citation>Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ 2017;358:j4008.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5833365</ArticleId><ArticleId IdType="pubmed">28935701</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne JAC, Savovi&#x107; J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials.BMJ 2019;366:l4898.</Citation><ArticleIdList><ArticleId IdType="pubmed">31462531</ArticleId></ArticleIdList></Reference><Reference><Citation>DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">3802833</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC192859</ArticleId><ArticleId IdType="pubmed">12958120</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenstock J, Bajaj HS, Jane&#x17e; A, et al. Once-Weekly insulin for type 2 diabetes without previous insulin treatment. N Engl J Med 2020;383:2107&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">32960514</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajaj HS, Bergenstal RM, Christoffersen A, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine u100 in type 2 diabetes inadequately controlled on daily basal insulin: a phase 2 randomized controlled trial. Diabetes Care 2021;44:1586&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8323191</ArticleId><ArticleId IdType="pubmed">33875485</ArticleId></ArticleIdList></Reference><Reference><Citation>Lingvay I, Buse JB, Franek E, et al. A randomized, open-label comparison of once-weekly insulin icodec titration strategies versus once-daily insulin glargine U100. Diabetes Care 2021;44:1595&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8323172</ArticleId><ArticleId IdType="pubmed">33875484</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathieu C, &#xc1;sbj&#xf6;rnsd&#xf3;ttir B, Bajaj HS, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial. Lancet 2023;401:1929&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">37156252</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenstock J, Bain SC, Gowda A, et al. Weekly icodec versus daily glargine u100 in type 2 diabetes without previous insulin. N Engl J Med 2023;389:297&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">37356066</ArticleId></ArticleIdList></Reference><Reference><Citation>American Diabetes Association. 6. glycemic targets: standards of medical care in diabetes-2021. Diabetes Care 2021. 44:S73&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">33298417</ArticleId></ArticleIdList></Reference><Reference><Citation>Hub&#xe1;lek F, Cramer CN, Helleberg H, et al. Enhanced disulphide bond stability contributes to the once-weekly profile of insulin icodec. Nat Commun 2024;15:6124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11271312</ArticleId><ArticleId IdType="pubmed">39033137</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh AK, Singh A, Singh R, et al. Once-weekly basal insulin icodec: looking ONWARDS from pharmacology to clinical trials. Diabetes Metab Syndr 2022;16:102615.</Citation><ArticleIdList><ArticleId IdType="pubmed">36108418</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentile S, Strollo F, Ceriello A. On behalf of the AMD-OSDI Injection Technique Study Group, Gentile S, Botta A, et al. Lipodystrophy in insulin-treated subjects and other injection-site skin reactions: are we sure everything is clear? Diabetes Ther 2016;7:401&#x2013;09.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5014793</ArticleId><ArticleId IdType="pubmed">27456528</ArticleId></ArticleIdList></Reference><Reference><Citation>Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC27454</ArticleId><ArticleId IdType="pubmed">10938048</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajaj HS, &#xc1;sbj&#xf6;rnsd&#xf3;ttir B, Bari TJ, et al. Once-weekly insulin icodec compared with daily basal insulin analogues in type 2 diabetes: participant-level meta-analysis of the ONWARDS 1-5 trials. Diabetes Obes Metab 2024;26:3810&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">38951942</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva RRE, de MGM, Guisso MES, et al. Once-weekly insulin icodec vs. once-daily insulin glargine U100 for type 2 diabetes: a systematic review and meta-analysis of phase 2 randomized controlled trials. Arch Endocrinol Metab 2023; 67:e000614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10665058</ArticleId><ArticleId IdType="pubmed">37249450</ArticleId></ArticleIdList></Reference><Reference><Citation>Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care 2019;42:1593&#x2013;603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6973648</ArticleId><ArticleId IdType="pubmed">31177185</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of time in range as an outcome measure for diabetes clinical trials. Diabetes Care 2019;42:400&#x2013;05.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6905478</ArticleId><ArticleId IdType="pubmed">30352896</ArticleId></ArticleIdList></Reference><Reference><Citation>Blonde L. Benefits and risks for intensive glycemic control in patients with diabetes mellitus. Am J Med Sci 2012;343:17&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">22205061</ArticleId></ArticleIdList></Reference><Reference><Citation>Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005;28:2673&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pubmed">16249538</ArticleId></ArticleIdList></Reference><Reference><Citation>Philis-Tsimikas A. Initiating basal insulin therapy in type 2 diabetes: practical steps to optimize glycemic control. Am J Med 2013;126:S21&#x2013;S27.</Citation><ArticleIdList><ArticleId IdType="pubmed">23953076</ArticleId></ArticleIdList></Reference><Reference><Citation>Abuelazm M, Ibrahim AA, Khlidj Y, et al. Once-weekly insulin icodec versus once-daily long-acting insulin for type II diabetes: a meta-analysis of randomized controlled trials. J Endocr Soc 2024;8:bvad177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10783254</ArticleId><ArticleId IdType="pubmed">38213906</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell-Jones D, Babazono T, Cailleteau R, et al. Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial. Lancet 2023;402:1636&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">37863084</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukhopadhyay P, Chatterjee P, Pandit K, et al. Once-weekly insulin icodec as compared to once-daily basal insulins: a meta-analysis. Endocr Pract 2024;30:128&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">37984730</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>